Transforming growth factor-81 (TGF-81 ) selectively modulates hematopoietic cell proliferation. The proliferation of FDC-P1 clone MAC-I 1, a factor-dependent murine myeloid progenitor cell line, was inhibited differentially by TGF-81 : strongly in macrophage colony-stimulating factor (M-CSF), mildly in interleukin-3, and not at all in granulocyte-macrophage-CSF (GM-CSF). Flow cytometry and Western blots showed an unexpected increase in expression of FMS, the receptor for M-CSF, in response to TGF-81. Metabolic labeling with j5S-methionine showed that synthesis of FMS protein accelerated in response to TGF-81 , whereas its degradation was unaffected. Northern analyses showed a RANSFORMING growth factor-01 (TGF-P1) is a
T member of a family of proteins that regulate cell growth and differentiation.'.' Although defined as a factor that induces anchorage-independent growth of fibroblast^,^.^ it can stimulate or inhibit proliferation of epithelial cells and fibroblasts, depending on cell type and growth conditions such as the presence of other growth factors.5s6 TGF-P1 has potent effects in hematopoie~is.'~~ It is present in the hematopoietic microenvironment, with major stores synthesized by megakaryocyte~.~ Also, in long-term bone marrow cultures, stromal cells constitutively synthesize TGF-/3 1 and antibodies that neutralize TGF-(I 1 activate progenitor cells to proliferate." TGF-61 appears to exert differential effects on hematopoiesis. It inhibits proliferation of differentiation-competent murine progenitor cell lines more than those incapable of differentiation." In assays of freshly isolated bone marrow cells, inhibition tends to correlate with earlier states of differentiation,12-" but it is unclear whether the basis for the different responses is the cell type, level of maturation, or colony-stimdating factor (CSF). TGF-P 1 inhibits macrophage-CSF (M-CSF)-dependent proliferation but enhances granulocytemacrophage-CSF (GM-CSF)-dependent proliferation of a homogeneous population of murine peritoneal exudate macrophages,I6 an effect attributable solely to different CSFs.
To date, the only proposed mechanism of selective growth inhibition by TGF-/3 1 is transmodulation of CSF receptor expression. TGF-PI inhibits interleukin-3 (IL-3)-induced expression of IL-1 receptors"; inhibits GM-CSF, G-CSF, and IL-3 receptor expression on murine progenitor cell lines"; and stimulates GM-CSF receptor expression on early murine progenitor cells recovered 3 days after 5-fluorouracil (5FU) treatment.I5 These effects on receptor expression all correlate with the effect of TGF-P1 on proliferation of the cells studied. However, this mechanism fails to explain some instances of factor-selective inhibition. Although in peritoneal macrophages GM-CSF receptor expression increases in parallel with their enhanced proliferation in response to TGF-PI, there is no modulation of the M-CSF receptor to account for its inhibition. l6 We have therefore undertaken studies of both receptor expression and function in an effort to understand how TGF-P 1 can selectively inhibit CSF-dependent proliferation.
We have previously reported the isolation from FDC-PI cells of a murine factor-dependent bipotential hematopoietic cell line, designated MAC-1 1. These cells simultaneously express receptors for IL-3, GM-CSF, and M-CSF.I9 In the present study, we have used this cell line to study the mechanism of selective growth inhibition by TGF-P1.
MATERIALS AND METHODS
Cells and cell culture. FDC-PI clone MAC-1 were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone, Logan, UT). WEHI-3B conditioned medium (WCM) was used as a source of IL-3 at a concentration sufficient for maximal proliferation (2%). Recombinant murine M-CSF was expressed in yeast and purified over a diethyl aminoethyl (DEAE)-cellulose column (yM-CSF)*' and subsequently was produced by expression of a baculovirus vector in Sf9 insect cells (Z. Wang et al, manuscript submitted). Recombinant murine GM-CSF was obtained from Immunex (Seattle, WA). Recombinant human TGF-p 1 was provided by Oncogen (Seattle, WA).
Quadruplicate cultures were seeded with 200 cells in l mL 0.3% Bacto-agar containing 200 U/mL yM-CSF and various concentrations of TGF-PI. After 7 days at 37"C, 10% COz, the cultures were fixed with 2.5% glutaraldehyde, dried onto glass slides, and stained with May-Griinwald Giemsa for colony counting.
For cell cycle analysis, cells were resuspended at 106/mL in 1 mL ice-cold media, 0.25 mL staining solution (propidium iodide 125 jtg/mL, I% Triton X-100. RNAse 250,000 U/ mL) was added, and the cells were incubated on ice for 5 to 45 minutes before analysis on the FACscan (Becton Dickinson, Mountain View, CA). Statistics on cell cycle phases were generated using the Multicycle computer program (Phoenix Flow SoFhvare, Phoenix, AZ).
To 22 For cell surface immunoprecipitation of FMS, tumor-bearing rat serum, after adsorption on FDC-PI cells, was diluted 1:250 and incubated with intact cells that were then washed extensively and lysed. MYC was immunoprecipitated using affinity-purified rabbit antiserum raised against the species-specific C-terminal peptide, generously provided by Dr R. Eisenman (FHCRC). Control serum was blocked by preincubation with the immunizing peptide at 10 ng/mL.
Immunoprecipitated FMS and MYC were electrophoresed on 7.5% and 10% sodium dodecyl sulfate (SDS)-polyacrylamide gels, respectively. For Western transfer to nitrocellulose, a dry blot transfer system (Ellard, Seattle, WA) was used at 0.67 mA/cm2 for 2 hours. Filters were blocked in TTBS (1 50 mmol/L NaCl, 25 mmol/L Tris-C1, pH 8 .0, and 0.5% Tween 20) with 3% gelatin for Iz5I, with 5% non-fat dry milk for chemiluminescence, and with I% bovine serum albumin and 1% chicken ovalbumin for phosphotyrosine detection. FMS was detected using the rabbit antiserum; phosphotyrosine was detected using murine monoclonal PY-20 (ICN, Irvine, CA).
In vitro kinase assays were performed with FMS immunoprecipitates at 30°C for 10 minutes in the presence of y-32P-ATP and 10 mmol/L MnC1, at pH 5.2, as detailed previou~ly.~~ Total RNA was extracted by the guanidinium isothiocyanate lysis and CsCl sedimentation method24 and analyzed after glyoxalation by electrophoresis through I .2% agarose gels, followed by capillary or vacuum (Vacugene; Pharmacia LKB, Uppsala, Sweden) transfer onto nitrocellulose. Blots were hybridized with nicktranslated probes: for c-fins, the Apa-EcoRI fragment of ~755"; for c-myc, the 3.2-kb BamHI-Hind111 fragment of pM 104BH spanning exons 1 to 326; for c-fox, the full-length cDNA insert from pSP65fos2'; and for c-jun, the full-length cDNA insert from pJUN7'8 (obtained from Dr R. Eisenman, FHCRC). Blots were washed at a final stringency of 0.1 X SSC, 0.1% SDS, 65°C for 30 to 60 minutes.
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RESULTS
Selective inhibition ofproliferution by TGF-PI. TGF-PI inhibits proliferation of various bone marrow progenitor populations differentially, depending on the CSF in which they are grown."-I4 This implies that TGF-01 interacts selectively with certain CSF receptors or interacts selectively with certain cell types whose proliferation is selectively induced by the various CSFs. We investigated the possibility of selective interaction with CSF receptors by testing the effect of TGF-P 1 on proliferation of the MAC-1 1 cell line. MAC-1 1 cells proliferate indefinitely as undifferentiated blast cells in either GM-CSF or IL-3. M-CSF induces both growth and some differentiation with limited expression of some macrophage markers." In the presence of TGF-P I , proliferation of MAC-11 cells was strongly inhibited in liquid cultures growing exponentially in M-CSF, whereas their proliferation was not inhibited when GM-CSF was the growth factor ( occurred at about 1 ng/mL TGF-PI (40 pmol/L). Differences in cell density were apparent within 24 hours and became more dramatic with time.
A change in cell morphology preceded detectable growth inhibition by TGF-P1. Cells in M-CSF became flatter and more adherent to tissue culture plastic or glass slides within 2 hours of addition of TGF-(31 (Fig 2) . This raised the possibility that increased adherence may mediate slower growth.
However, growth inhibition did not depend on induction of adherence, because TGF-P 1 inhibited proliferation even when the cells were cultured in polypropylene tubes to which they could not adhere (Fig 3) .
Growth inhibition observed in bulk liquid cultures may result from reduction of the proportion of cells proliferating or the rate of proliferation of each cell. To dissect the contributions of these mechanisms, we performed colony-forming assays. In 7-day soft agar cultures of MAC-1 1 cells in M-CSF (Table l) , low concentrations of TGF-P1 did not affect cloning efficiency, but reduced the size of colonies and altered colony morphology from compact to dispersed. At or above 10 ng/mL TGF-P I , no colonies formed in M-CSF.
Because proliferation in response to M-CSF was preferentially inhibited by TGF-P 1, we expected that trans-modulation of FMS expression might be a mechanism ofgrowth inhibition. However, both by flow cytometry (Fig 4A) and by Westem blotting (Fig 4B) mature band appeared within I hour, followed at 2 to 4 hours by a similar increase in the fully glycosylated 165-Kd form. Increased FMS expression persisted for at least 7 days in the continuous presence of TGF-81. Metabolic labeling experiments in which cells were pulsed for 30 minutes with 3SS-methionine and chased for 0 to 4 hours showed that, after TGF-81 exposure, the signal increased in each FMS band, signifying more rapid synthesis (Fig 5) . TGF-@I exposure did not affect the rate of degradation. When M-CSF was present, most FMS disappeared from the cell surface within 60 minutes of synthesis, and without M-CSF the half-life was about 4 hours. The diminished signal at the 40-minute time point (Fig 5) without M-CSF and without TGF-81 was not typical. For Northern blot analysis (Fig 6) showed an increase in c-fms RNA beginning within 30 minutes after the addition of TGF-PI, preceding the increase in protein synthesis. The response to TGF-PI did not require simultaneous presence of M-CSF (data not shown). We have previously shown that both GM-CSF and IL-3 can trans-downmodulate cTfms expression at the RNA level." The effect of GM-CSF is dominant to M-CSF and is mediated by induction of RNase activity.*' The results in Fig 6 also indicate that GM-CSF-dependent transdownmodulation was dominant to the TGF-PI-induced increase in clfins expression.
We considered the possibility that, although FMS was expressed at higher levels in cells exposed to TGF-PI, it may be functionally inhibited by posttranslational modification or other factors induced by TGF-P I. However, assays of endogenous kinase activity performed on immunoprecipitated receptor showed that "P incorporation was in all cases proportionate to the amount of FMS detectable in parallel Western blots (Fig 7) . To exclude the possibility that FMS may be regulated by interactions that take place only in intact cells, we also examined the cellular phosphoprotein response to M-CSF. TGF-PI did not affect the amount of phosphotyrosine detectable by Western blots of immunoprecipitated FMS after cells were stimulated by M-CSF. In cells lysed within 10 minutes after M-CSF stimulation, the strongest phosphotyrosine signal is from transphosphorylated FMS, but one can detect tyrosine phosphorylation of several other proteins, some of which presumably are substrates of FMS. When whole lysates of cells stimulated with M-CSF were immunoblotted for phosphotyrosine, the pattern of bands in the presence of TGF-PI was indistinguishable from controls without TGF-PI (data not shown).
After stimulation by M-CSF, V-FMS is rapidly internalized in clathrin-coated pits29 and transported via endosomes to lysosomes where it is degraded.30 In addition to terminating the signal, it is possible that association with coated pits and internalization play an active role in receptor function by providing access to Preservafion (?f FMS kinase acf ivify.
Prmervation of FMS internalizafion.
-gp1S -gp140 -M-CSF 18s -substrates at different intracellular locations. Because we observed that cells deprived of M-CSF upmodulated expression of FMS to a level comparable to that of cells exposed to both TGF-PI and M-CSF (Fig 7) , we considered the possibility that TGF-PI may prevent M-CSF-induced downmodulation of FMS. We measured internalization of FMS as the loss of receptor immunoprecipitable from the cell surface upon stimulation with M-CSF. Incubation with TGF-PI for up to 48 hours before the internalization assay had no effect, consistent with the results of the metabolic labeling experiments that showed a primary effect on synthesis, not degradation (data not shown). Specific inhibition bv TGF-PI of FMS-induced c-myc expression. Because TGF-Dl selectively inhibited M-CSFdriven proliferation without reducing FMS expression or inhibiting early functions of the receptor, we surmised that downstream signal transduction events must be inhibited. A mutant of c,fins that fails to induce c-myc is defective in proliferation and can be rescued by coexpression of c -m y~,~' implying that MYC performs functions that are essential for FMS-stimulated proliferation. Because c-myc is also a target of TGF-PI inhibition in keratin~cytes,~~ we tested its role in our hematopoietic system. In Table 2 and Fig  9) . TGF-PI did not affect cell cycle progression of MAC-! I cells stimulated by GM-CSF.
Cell cvcle analvsis.

DISCUSSION
TGF-PI is a potent inhibitor of proliferation of most hematopoietic cells7~x; however, its mechanism ofaction remains to be fully elucidated. Because responses differ among cell types and depend on the level of maturation and on which CSFs are p r e~e n t ,~. " -~~.~~ it was predicted that modulation of CSF receptors might be a mechanism whereby TGF-PI inhibits proliferation. Indeed, several examples illustrate this -SIP165 -gP1N phenomen~n.'~-'~ The present study shows the antithesis: although TGF-81 maximally inhibits proliferation of MAC-1 I cells when they are growing in response to M-CSF, expression of FMS, the receptor for M-CSF, was increased by TGFPl. Instead, TGF-Dl appeared to inhibit FMS-dependent expression of c-myc, a proto-oncogene involved in growth regulation.
gP1& -gP1@
We have used the MAC-1 I cloned continuous cell line, which remains dependent on any of three CSFs for survival and proliferation. Its proliferative behavior was consistent with that of freshly isolated bone marrow progenitors, whose proliferation in response to M-CSF is also inhibited by TGF-I. 15-35-36 Recently, several groups have described differential effects of TGF-P1 on primary marrow progenitors''*'5 and tissue macrophagesI6 with inhibition in M-CSF and responses in GM-CSF ranging from little effect to synergistic stimulation. These observations suggest the validity of the MAC-1 1 cell line as a model for bipotential progenitor cells. Our use of this cloned cell line excludes the possibility of indirect effects mediated by contaminating stromal elements and the possibility that the cells that continue to proliferate in GM-CSF represent a subpopulation distinct from those whose proliferation in M-CSF is inhibited.
In an effort to resolve the apparent paradox between increased FMS expression and decreased FMS-mediated proliferation, we studied the known early events in receptor tyrosine kinase-mediated signal transduction. TGF-8 1 affected neither in vitro kinase activity of FMS nor tyrosine phosphorylation of FMS and other cellular targets in cells stimulated with M-CSF. Furthermore, M-CSF-induced internalization of FMS proceeded as usual, despite TGF-81 treatment. However, TGF-81 pretreatment rendered MAC-1 1 cells incapable of responding to M-CSF with increased cmyc expression, although c-fos and c-jun were induced to normal levels with normal kinetics. Roussel et a13' observed an identical pattern of early response gene induction in murine fibroblasts that express a point mutant of human c-fms in which the major autophosphorylation site, tyrosine 809, was eliminated by mutation to phenylalanine. In that system, constitutive overexpression of c-myc complements FMS Y809F for proliferation. Although TGF-01 may inhibit more than one function of FMS, c-myc induction was the only function we observed to be inhibited. Moreover, based on the observation that FMS requires cooperation from MYC?' and on the lack ofexamples ofcell proliferation without MYC function, we believe that the inhibition by TGF-P1 of FMSdependent c-myc induction can account for its growth inhibition. Formal proof will require overexpression of c-myc to rescue cells from growth inhibition by TGF-81, and these experiments are in progress.
MYC function is required for entry into S phase,32 and recent evidence suggests it also is required for exit from S phase to G2/M.33 We considered the possibility that inhibition of c-myc expression might arrest cells in late S phase, but found that the addition of TGF-81 to exponentially growing cultures of MAC-I 1 in M-CSF led to arrest in GO/G 1, as was shown for mink lung epithelial cells.37
Inhibition of c-myc expression by antisense oligonucleotides inhibits proliferation and promotes granulocytic differ- entiation of the human promyelocytic cell line, HL-60.38,39 We observed some features of increased differentiation in MAC-1 1 cells treated with TGF-P1: larger size, more granularity, increased adherence, increased FMS expression, and decreased proliferation. However, the cells did not acquire phagocytic activity, nor did they clearly alter their expression of differentiation antigens after treatment with TGF-01 (data not shown). It is possible that this pattern represents the defective differentiation of a continuous cell line, or other factors may be required for complete differentiation.
Our results are similar to those of Pietenpol et al,32 who have shown that in keratinocytes stimulated by epidermal growth factor (EGF) TGF-PI inhibits proliferation by inhibiting transcription of c-myc. They have identified a TGF-P1 response element between -86 and -63 relative to the cmyc promoter P1. We have yet to determine the mechanism of regulation of c-myc RNA levels in our model system. The work of Sherr et a13' suggests that a signal transducer that interacts with FMS phosphotyrosine 809 goes on to induce c-myc. Interruption of any element in this pathway by TGF-/3l could account for our observations. FMS Y809 is homologous with the residue ofthe plasma-derived growth factor receptor (PDGF-R) required for binding of pp6OSrc (Y857);O raising the possibility that pp6OSm participates in this pathway. Because there is no apparent homology between FMS Y809 and the mapped tyrosine phosphorylation sites of the EGF receptor, the initial signals for c-myc induction in EGF-stimulated keratinocytes and in M-CSF-stimulated hematopoietic cells appear to differ. If subsequent elements of the signalling pathway from FMS and the EGF-R to c-myc also differ, then the TGF-PI control element identified by Pietenpol et a13' may not be active in our system.
In lymphoid cells, a mutant IL-2RQ that fails to interact with the src-family tyrosine kinase p56ICk and does not affect cellular phosphotyrosine nevertheless induces c-myc in response to IL-2.33 Therefore, lymphoid cells possess a tyrosine kinase-independent signal transduction pathway from a member of the hematopoietin receptor family to c-myc. Fibroblasts possess a signal transduction pathway from FMS to c-myc that involves the FMS autophosphorylation site Y809.31 The present study shows for the first time that a single cell possesses distinct pathways of c-myc induction by a member of the hematopoietin receptor family (the GM-CSF receptor) and a receptor tyrosine kinase (FMS), and that these pathways constitute a mechanism of selective growth inhibition by TGF-/3 1. Because early hematopoietic cells express receptors that are highly homologous to FMS, this may be a general mechanism whereby TGF-/3 1 selectively inhibits proliferation of early hematopoietic cells.
